ArticleJournal of ophthalmic inflammation and infection2025
Multizonal outer retinopathy and retinal pigment epitheliopathy (MORR) with a chronologically divergent presentation- a case report.
Article in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute zonal occult outer retinopathy (AZOOR) is a rare inflammatory disease of the outer retina, often presented with subtle early findings. A specific subtype, termed Multizonal Outer Retinopathy and Retinal Pigment Epitheliopathy (MORR), is characterized by distinct progression pattern (Ramtohul et al. Retina 43:1890–1903, 2023) in multiple zones of the outer retina and retinal pigment epithelium. This case report aims to illustrate the chronologically divergent presentation, a phase-shifting disease progression and the complex clinical course of MORR, and to discuss the diagnostic challenges posed by its phase‑shifted timeline as well as potential therapeutic options.
methodsA case of a 52-year-old female patient with initially unilateral, inactive posterior uveitis was retrospectively analyzed. Over thirteen years, progressive functional impairment developed in the fellow eye. Findings were assessed using multimodal imaging (Optical Coherence Tomography [OCT], Fundus Autofluorescence [FAF], Fluorescein and Indocyanine Green Angiography [FFA/ICGA]) and electrophysiological examinations (multifocal ERG, full-field ERG, EOG, VEP). Additional rheumatologic and neurologic assessments were conducted, and an infectious workup was performed.
resultsThe patient demonstrated chronologically divergent bilateral involvement with extensive damage to the retinal pigment epithelium (RPE) and photoreceptors. Fundus autofluorescence revealed a tri- to multizonal pattern in the better eye, while the fellow eye already exhibited diffuse atrophic areas devoid of any autofluorescence. Electrophysiological, the better eye showed selectively prolonged latencies on multifocal electroretinography (multifocal ERG) but preserved amplitudes, whereas the more severely affected eye displayed substantial functional loss. Despite various therapeutic interventions, including high-dose corticosteroids and immunosuppressive agents, progressive visual impairment ensued, driven by increasing macular involvement.
conclusionsThis case highlights the marked heterogeneity and diagnostic complexities of Multizonal Outer Retinopathy and Retinal Pigment Epitheliopathy (MORR), a newly recognized progressive variant of Acute Zonal Occult Outer Retinopathy (AZOOR). The disease course can present with chronologically divergent manifestations in both eyes. While initial stages may exhibit only subtle funduscopic changes, structural and functional deficits can progress rapidly, episodically and in a phase-shifted manner. Multimodal imaging is essential to delineate the disease trajectory and to distinguish MORR from diseases affecting outer retina. Currently, no definitive treatment is available; although immunomodulatory therapies may stabilize the condition in certain cases, their efficacy remains inconsistent. Consequently, early low-vision management and close interdisciplinary collaboration are of particular importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.